PF-Atlas › Drugs › Nerandomilast

Nerandomilast

Idiopathic Pulmonary Fibrosis · PDE4B Inhibition

Clinical trials
7
Mechanism
PDE4B Inhibition
Development stage
FDA Approved Oct 2025
Evidence level
Level 1 (FDA Approved)
Developer
Boehringer Ingelheim

Overview

FDA approved Oct 2025 for IPF, Dec 2025 for PPF. First new IPF drug in a decade. FIBRONEER-IPF/ILD Phase III: significantly reduced FVC decline vs placebo, works with or without nintedanib/pirfenidone. Oral, once daily.

Nerandomilast clinical trials

FIBRONEER-IPF (Phase 3)FIBRONEER-ILD (Phase 3)NCT07201922 (Phase 3)NCT07366034 (Phase 3)NCT06238622 (Phase 3)NCT07540988 (Phase 3)NCT06806592 (Phase 3)

Explore related

Treatment profilePDE4B InhibitionAll trialsResearch
Medical disclaimer. This page summarizes research about Nerandomilast for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.